RUNX1抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using RUNX1 mouse mAb against Jurkat cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using RUNX1 mouse mAb (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

**Background of RUNX1 Antibody**

The RUNX1 (Runt-related transcription factor 1) antibody is a critical tool for studying the RUNX1 protein, a member of the RUNX family of transcription factors that play pivotal roles in hematopoiesis, cellular differentiation, and oncogenesis. RUNX1. also known as AML1 (Acute Myeloid Leukemia 1), binds DNA via its conserved Runt domain and regulates gene expression by forming complexes with co-factors like CBFβ. It is essential for the development of hematopoietic stem cells and megakaryocyte maturation.

Dysregulation or mutations in RUNX1 are closely associated with hematologic malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Somatic mutations, chromosomal translocations (e.g., RUNX1-ETO in t(8;21) AML), or inherited RUNX1 variants can disrupt its normal function, leading to impaired differentiation and proliferation of blood cells.

RUNX1 antibodies are widely used in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). They also aid in diagnosing RUNX1-related disorders and evaluating therapeutic targets. Specific antibodies may recognize different isoforms (e.g., RUNX1a, b, c) or post-translational modifications, enabling precise investigation of its roles in health and disease. As RUNX1 continues to be a focus of cancer biology and stem cell research, its antibody remains indispensable for both basic and clinical studies.